08:00 , Jan 14, 2002 |  BioCentury  |  Finance

Hat in Hand?

Hat in Hand? Company Raised in 1H00 Notes diaDexus $102.5M Filed for IPO in11/00 Athersys $47.5M Withdrew IPO on 4/01 DoubleTwist $37.0M Withdrew IPO on 3/01 Structural Bio $32.6M Quantum Dot $30.0M BioStratum $28.0M Delsys...
08:00 , Dec 17, 2001 |  BC Week In Review  |  Company News

Amplistar other research news

Researchers published in the Proceedings of the National Academy of Sciences evidence that the homeobox gene HOXA7 product is selectively expressed on certain differentiated ovarian tumors and stimulates an immune response in patients. Analysis of...
07:00 , Aug 27, 2001 |  BioCentury  |  Finance

Money Hunters

Money Hunters Company Amt raised in 1H00 Notes diaDexus $102.5M Filed for IPO 11/20/00 Athersys $47.5M Withdrew IPO 4/17/01 DoubleTwist $37.0M Withdrew IPO 3/7/01 Structural Bio $32.6M 454 $32.5M Curagen spinoff Xenogen $30.5M Withdrew IPO...
07:00 , Aug 27, 2001 |  BioCentury  |  Finance

Money Hunters

Money Hunters Company Amt raised in 1H00 Notes diaDexus $102.5M Filed for IPO 11/20/00 Athersys $47.5M Withdrew IPO 4/17/01 DoubleTwist $37.0M Withdrew IPO 3/7/01 Structural Bio $32.6M 454 $32.5M Curagen spinoff Xenogen $30.5M Withdrew IPO...
07:00 , Apr 9, 2001 |  BC Week In Review  |  Company News

Amplistar, Johns Hopkins University deal

Amplistar received an exclusive worldwide license from the university to ovarian-related gene products that stimulate an immune reaction in ovarian cancer patients. The license includes rights to the HOXB7 gene product, which researchers at the...